Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas
Daphne A. Haas‐Kogan(Brigham and Women's Hospital), L. Kun(Radiation Oncology Associates), Mehmet Koçak(St. Jude Children's Research Hospital), Alberto Broniscer(St Nicholas Hospital), A. Banerjee(Cincinnati Children's Hospital Medical Center), J. Geyer(Cincinnati Children's Hospital Medical Center), Maryam Fouladi(Nationwide Children's Hospital), Jane E. Minturn(St Nicholas Hospital), Ian F. Pollack(Children's Hospital of Pittsburgh), James M. Boyett(University of Illinois Chicago), Tina Young Poussaint(Seattle Children's Hospital), R. J. Packer(Cincinnati Children's Hospital Medical Center), M. D. Prados(Cincinnati Children's Hospital Medical Center)
Cited by 88
Related Papers
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711
Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease
|Journal of Clinical Oncology|2010|657
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488